9th ANNUAL CASE BASED APPROACH TO CONTROVERSIES IN CARDIOVASCULAR DISEASES

March 1st - 2nd, 2019
Mohammed Bin Rashid
Academic Medical Center
Dubai Healthcare City, Dubai, UAE
www.CVUAE.com
#CVUAE | #IPEvents

CONFERENCE BOOK
Sheikh Hamdan Bin Rashid Al Maktoum
Award for Medical Sciences

20 YEARS OF EXCELLENCE
Course Directors & Committees

Course Directors

Walid Saliba, MD
Staff, Section of Cardiac Electrophysiology and Pacing Department of Cardiovascular Medicine Heart and Vascular Institute Ohio, USA

Joseph Maalouf, MD
Professor of Medicine Mayo Clinic College of Medicine Consultant Cardiovascular Diseases and Internal Medicine Director Interventional Echocardiography Mayo Clinic, Rochester Minnesota, USA

Wael Adbulrahman Al Mahmeed, MD
Consultant Cardiologist at the Heart and Vascular Institute Abu Dhabi, UAE

US Organizing Committee

Katherine Hoercher, RN
Senior Director Heart and Vascular Institute Ohio, USA

Wael Jaber, MD
Staff, Section of Cardiovascular Imaging Department of Cardiovascular Medicine and Vascular Institute Ohio, USA

Join the conversation at #CVUAE Your input matters!
Faculty

Cleveland Clinic

Faisal Bakaeen, MD
Staff, Department of Thoracic and Cardiovascular Surgery
Heart and Vascular Institute
Ohio, USA

Brian Griffin, MD
Section Head, Cardiovascular Imaging Department of Cardiovascular Medicine
Heart and Vascular Institute
Ohio, USA

Katherine Hoercher, RN
Senior Director, Heart and Vascular Institute
Ohio, USA

Wael Jaber, MD
Staff, Section of Cardiovascular Imaging
Department of Cardiovascular Medicine, Heart and Vascular Institute
Ohio, USA

Venu Menon, MD
Staff, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine
Heart and Vascular Institute
Ohio, USA

Walid Saliba, MD
Staff, Section of Cardiac Electrophysiology and Pacing Department of Cardiovascular Medicine
Heart and Vascular Institute
Ohio, USA

Oussama Wazni, MD
Staff, Section of Cardiac Electrophysiology and Pacing Department of Cardiovascular Medicine
Heart and Vascular Institute
Ohio, USA

Mayo Clinic

Daniel Borgeson, MD
Assistant Professor of Medicine
Mayo Clinic College of Medicine and Science
Consultant for Department of Cardiovascular Medicine
Ohio, USA

Joseph Maalouf, MD
Professor of Medicine
Mayo Clinic College of Medicine Consultant
Cardiovascular Diseases and Internal Medicine Director
Interventional Echocardiography
Mayo Clinic, Rochester
Minnesota, USA

Amy Pollak MD
Assistant Professor of Medicine
Mayo Clinic College of Medicine Consultant, Cardiovascular Diseases and Internal Medicine
Mayo Clinic
Jacksonville, Florida, USA

Peter Pollak MD
Senior Associate Consultant Invasive and Interventional Cardiology Mayo Clinic
Jacksonville, Florida, USA

Join the conversation at #CVUAEE Your input matters!

www.CVUAEE.com
Faculty

Cleveland Clinic Abu Dhabi

Wael Adbulrahman
Al Mahmeed, MD
Consultant Cardiologist at the Heart and Vascular Institute Abu Dhabi, UAE

Khalid Al Mufi, MD
Consultant Physician Cardiac Electrophysiology & Cardiovascular Disease Abu Dhabi, UAE

Bassam Atallah, Pharm D
M.S., BCPS-AQ Cardiology, FHFSA Pharmacotherapy Specialist-Cardiology Department of Pharmacy Services Heart Failure Society of America Middle East Ambassador Cleveland Clinic Abu Dhabi Abu Dhabi, UAE

Feras Bader, MD
Clinical Associate Professor of Medicine Director, Section of Heart Failure and Transplant Heart & Vascular Institute Chairman, Heart Failure Working Group of Emirates Cardiac Society Abu Dhabi, UAE

Ahmad Edris, MD
Consultant Physician Abu Dhabi, UAE

Mohammed Khalil, MD
Clinical Assistant Professor Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Director of Imaging & Clinical Services Heart and Vascular Institute Cleveland Clinic Abu Dhabi Abu Dhabi, UAE

Dima Quraini, MD
Staff physician at the Heart and Vascular Institute at Cleveland Clinic Abu Dhabi, UAE

Hussein Saadi, MD
Chair, Medical Subspecialties Institute, Clinical Professor of Medicine Cleveland Clinic Abu Dhabi, UAE

Hani Sabbour, MD
Staff Physician in the Heart and Vascular Institute at Cleveland Clinic Abu Dhabi, UAE

Murat Tuzcu, MD
Professor of Medicine Chief Academic Officer Chairman, Heart and Vascular Institute Chairman, Department of Cardiovascular Medicine Abu Dhabi, UAE

Join the conversation at #CVUAE Your input matters! www.CVUAE.com
Faculty

Regional and Local

Bernard Abi Saleh, MD
Cardiac Electrophysiology
American University of Beirut Faculty of Medicine and Medical Center Lebanon

Safaa Al Mohdar, MD
Dubai, UAE

Jumaa Al Dhaheri
Consultant Invasive Adult Cardiology
Chief of Medicine
Zayed Military Hospital
Abu Dhabi, UAE

Mohamed Al Jaabari, MD
Consultant Cardiologist
Sheikh Khalifa Medical City
Abu Dhabi, UAE

Obaid Al Jassim, MD
Consultant Cardiothoracic Surgeon, Dubai Hospital
Dubai, UAE

Sultan Al Karam, MD
Chief Medical Officer
Tawam Hospital
Dubai, UAE

Fahad Al Sindi, MD
Consultant Heart Failure Cardiologist, Mohd Bin Khalifa Cardiac Center
Bahrain

Abdulmajid Al Zubaidi, MD
Dubai, UAE

Walid Alami, MD
Interventional Cardiologist
Lebanon

Ghaliah Almohany, MD
Senior Consultant interventional and Electrophysiologist, National Heart Institute
Muscat, Oman
Faculty

Regional and Local

Nooshin Bazargani, MD
Consultant Cardiologist
Dubai Hospital
Dubai, UAE

Moutaz El Kadri, MD
Consultant cardiologist and
Electrophysiologist
Sheikh Khalifa Medical City
Dubai, UAE

Hussain Ismaeel, MD
Associate Professor of
Clinical Medicine
Director, Vascular
Medicine Program
Division of Cardiology
American University of Beirut
Lebanon

Adel Khalifa, MD
Consultant Cardiologist &
Interventional Cardiac
Electrophysiologist
Head of Electrophysiology
Department
Bahrain

Mohamad Magdi, MD
Dubai, UAE

Marwan Refaat, MD
Associate Professor of Medicine
and Biochemistry
Internal Medicine
Biochemistry & Molecular Genetics
Director, Cardiovascular
Fellowship Program
Member, Division of Cardiology
Section of Cardiac Electrophysiology
Lebanon

Hosam Zaky, MD
Consultant Cardiologist
MS,MD.,(Cardiology)
MRCP,(UK),FGHA,FASE,FACC.
American Board ECHO
European Board PAC/Defib
Dubai, UAE
### Scientific Program

**First Day - Friday**  
**1st March, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:20</td>
<td>Registration and Coffee</td>
<td></td>
</tr>
<tr>
<td>08:20 - 08:30</td>
<td>Welcome and Opening Remarks</td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:50</td>
<td>Session I: Transcatheter Valvular Therapies: Patient Selection and Outcomes</td>
<td>Ahmad Edris, Faisal Bakaeen, Obaid Al Jassim, Juma Al Dhaheri, Bassam Atallah</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td>Patient with functional MR: Surgery versus Clip</td>
<td>Brian Griffin</td>
</tr>
<tr>
<td>08:50 - 09:10</td>
<td>Patient with failed mitral bioprosthesis</td>
<td>Peter Pollak</td>
</tr>
<tr>
<td>09:10 - 09:30</td>
<td>Morbidly Obese Patient post TAVR with MS and AF: Choosing antithrombotic therapy</td>
<td>Bassam Attallah</td>
</tr>
<tr>
<td>09:30 - 09:50</td>
<td>Low Risk Patient with AS: TAVR or SAVR</td>
<td>Peter Pollak</td>
</tr>
<tr>
<td>09:50 - 10:10</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:10 - 10:50</td>
<td>Session II: Prevention and Management of HTN and Dyslipidemia</td>
<td>Amy Pollak, Hanni Sabbour, Joseph Maalouf</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>The Healthy patient with hypertension: Would you do a calcium score test?</td>
<td>Hussain Ismaeel</td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td>PCSK9: does it affect cognition? Good for everyone?</td>
<td>Amy Pollak</td>
</tr>
<tr>
<td>10:50 - 11:20</td>
<td>Industry Symposium</td>
<td>Novartis</td>
</tr>
<tr>
<td>11:20 - 11:50</td>
<td>Industry Symposium</td>
<td>Novartis</td>
</tr>
<tr>
<td>11:50 - 12:20</td>
<td>Industry Symposium</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>12:20 - 13:30</td>
<td>Lunch and Friday Prayer</td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:30</td>
<td>Session III: Focus on AF Management</td>
<td>Khalid Almuti, Marwan Refaat, Mohamad Magdi, Hosam Zaky, Mohamed Al Jaabari</td>
</tr>
<tr>
<td>13:30 - 13:50</td>
<td>47 year old patient with AFib and LA clot</td>
<td>Walid Saliba</td>
</tr>
<tr>
<td>13:50 - 14:10</td>
<td>75 year old female with high CHADSVASC score and GI bleeding</td>
<td>Adel Khalifa</td>
</tr>
<tr>
<td>14:10 - 14:30</td>
<td>65 year old patient with LV dysfunction, VF and AF post CABG</td>
<td>Ghalia Al Mohanni</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td>60 year old with LV dysfunction and AF</td>
<td>Oussama Wazni</td>
</tr>
<tr>
<td>14:50 - 15:20</td>
<td>Industry Symposium</td>
<td>Pfizer</td>
</tr>
<tr>
<td>15:20 - 15:40</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>15:40 - 16:40</td>
<td>Session IV: CV Risk Stratification and Management in Diabetics</td>
<td>Noosheen, Hussein Saadi, Joseph Maalouf</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>47 year old man with type 2 diabetes and recent acute coronary syndrome presents for an office visit</td>
<td>Venu Menon</td>
</tr>
<tr>
<td>16:00 - 16:20</td>
<td>Myocardial infarction with non-obstructive coronary arteries in a patient with diabetes</td>
<td>Amy Pollak</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td>54 year old man with diabetes and strong family history presents for an outpatient consultation</td>
<td>Venu Menon</td>
</tr>
<tr>
<td>16:40 - 17:20</td>
<td>Session V: EKG: Read with the Experts</td>
<td>Walid Saliba, Venu Menon, Oussama Wazni</td>
</tr>
</tbody>
</table>
## Scientific Program

### Second Day - Saturday 2nd March, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td>Registration and Welcome Coffee</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Session VI: Focus: on Myocardial Revascularization in the setting of CAD</td>
</tr>
<tr>
<td></td>
<td>Panel: Murat Tuzcu, Wael Jaber, Faisal Baakeen, Obaid Al Jassim,</td>
</tr>
<tr>
<td></td>
<td>Abdulmajid Al Zubaidi, Sultan Alkaram</td>
</tr>
<tr>
<td>09:00 - 09:20</td>
<td>Support devices in AMI and shock</td>
</tr>
<tr>
<td>09:20 - 09:40</td>
<td>Coronary disease and TAVR: treat or leave alone?</td>
</tr>
<tr>
<td>09:40 - 10:00</td>
<td>67 year old male with CAD and EF of 28%; Value of</td>
</tr>
<tr>
<td></td>
<td>Ischemia/hibernation testing to determine value of revascularization</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:20 - 11:00</td>
<td>Session VII: Gender Differences in Diagnosis and Management of CVD</td>
</tr>
<tr>
<td></td>
<td>Panel: Nooshin Bazargani, Dima Quraini, Juwairiah Tahir, Safa Almohdar,</td>
</tr>
<tr>
<td></td>
<td>Wael Almahmeed, Feras Bader</td>
</tr>
<tr>
<td>10:20 - 10:40</td>
<td>Patient with Postpartum cardiomyopathy</td>
</tr>
<tr>
<td>10:40 - 11:00</td>
<td>Patient with SCAD</td>
</tr>
<tr>
<td>11:00 - 11:20</td>
<td>MV disease in female planning a pregnancy</td>
</tr>
<tr>
<td>11:20 - 11:55</td>
<td>Industry Symposium</td>
</tr>
<tr>
<td></td>
<td>PCSK9 inhibitors</td>
</tr>
<tr>
<td>12:00 - 13:15</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>13:15 - 14:15</td>
<td>Session VIII: Focus on Heart Failure</td>
</tr>
<tr>
<td></td>
<td>Panel: Feras Bader, Dan Borgenson, Nooshin Bazargani, Mohammed Khalil,</td>
</tr>
<tr>
<td></td>
<td>Bassam Atallah</td>
</tr>
<tr>
<td>13:15 - 13:35</td>
<td>73 year old male with increasing shortness of breath and repeated hospitalizations</td>
</tr>
<tr>
<td>13:35 - 13:55</td>
<td>64 year old male with new LV dysfunction and severe MR</td>
</tr>
<tr>
<td>13:55 - 14:15</td>
<td>65 year old female with new onset LBBB and HF</td>
</tr>
<tr>
<td>14:15 - 15:15</td>
<td>Session IX: Focus on Ventricular arrhythmias</td>
</tr>
<tr>
<td></td>
<td>Panel: Khalid Al Muti, Ghalia Almohany, Mohammad Khalil, Adel Khalifa,</td>
</tr>
<tr>
<td></td>
<td>Walid Saliba, Motaz Kadri</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td>62 year old with new onset syncope and VF arrest</td>
</tr>
<tr>
<td>14:30 - 14:45</td>
<td>21 year old with palpitations and NSVT on Holter</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>67 year old man with severe lower extremity cellulitis VF storm</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>56 year old physician with Cardiac Mass</td>
</tr>
<tr>
<td>15:15 - 15:40</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:40 - 16:20</td>
<td>Session X: Read with the Experts: Imaging Interpretations</td>
</tr>
<tr>
<td></td>
<td>Panel: Wael Jaber, Joe Maalouf, Venu Menon, Brian Griffin, Mohammad Khalil</td>
</tr>
</tbody>
</table>

Join the conversation at #CVUAE Your input matters!
Prevention of stroke/systemic embolism in NVAF

Prevention of recurrent DVT and PE

Prophylaxis of VTE after hip replacement surgery

Prophylaxis of VTE after knee replacement surgery

Choose both efficacy and safety with ELIQUIS®

ELIQUIS® (Apixaban) Abbreviated Prescribing Information.

Presentation 2 Forms Available. One film-coated tablet contains 2.5 mg apixaban and one film-coated tablet contains 5 mg apixaban. INDICATIONS: 2.5 mg is indicated for the prevention of recurrent thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery, prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. 5 mg is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. INDICATIONS: 2.5 mg is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. (See Usage in Specific Populations, Special Populations). 5 mg is indicated for prevention of stroke and systemic embolism in adult patients with NVAF and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. (See Usage in Specific Populations, Special Populations). For prevention of recurrent DVT and PE in adults and treatment of DVT and PE in adults and at-risk PE. INDICATIONS: 2.5 mg is indicated for prevention of stroke and systemic embolism in adult patients with NVAF and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. INDICATIONS: 2.5 mg is indicated for prevention of stroke and systemic embolism in adult patients with NVAF and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. (See Usage in Specific Populations, Special Populations). 5 mg is indicated for prevention of stroke and systemic embolism in adult patients with NVAF and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. INDICATIONS: 2.5 mg is indicated for prevention of stroke and systemic embolism in adult patients with NVAF and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. INDICATIONS: 2.5 mg is indicated for prevention of stroke and systemic embolism in adult patients with NVAF and in adults with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years and younger, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class II-IV), and treatment of deep vein thrombosis (DVT) (including extension), and treatment of pulmonary embolism (PE) and at-risk PE. (See Usage in Specific Populations, Special Populations).

ELIQUIS® is a registered trademark of Pfizer NVAF: Non-Valvular Atrial Fibrillation PE: Pulmonary Embolism DVT: Deep Vein Thrombosis VTE: Venous Thromboembolism


Full prescribing information is available upon request.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 121,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

Website: www.novartis.com

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Website: www.sanofi.com

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group, Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Website: www.merck.ae
Start ENTRESTO® sooner in NYHA Class II patients with HFrEF for superior protection

Start ENTRESTO® today

The starting dose is 50 mg or 100 mg twice daily, depending on the patient’s current treatment and medical condition

The target dose is 200 mg twice daily

Stop using an ACE inhibitor for 1.5 days (36 hours) before starting ENTRESTO®

ENTRESTO® contains valsartan, and therefore should not be coadministered with another ARB-containing product.

Before your NYHA Class II patients with HFrEF leave your office, take action with ENTRESTO® and keep them on the right path.

In adults, for the treatment of primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia in combination with a statin or statin with other lipid lowering therapies; alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant and with a PRIOR CV EVENT - TIME FOR PRALUENT TO LOWER LDL-C

PRALUENT® (alirocumab) is the only PCSK9i with the choice of 2 powerful levels of efficacy

The effect of PRALUENT on cardiovascular morbidity and mortality has not yet been determined.

*CV event defined as any of the following that occurred at least 3 months prior to therapy: acute coronary syndrome, history of MI, stable or unstable angina, coronary/other revascularisation, or stroke or transient ischaemic attack.

SUMMARY OF SAFETY PROFILE
Most common adverse reactions were local injection site reactions, upper respiratory tract infections, and pruritus.
Most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were local injection site reactions.
No difference in the safety profile was observed between the 2 doses (75 mg Q2W and 150 mg Q2W) used in the phase 3 program.

PRALUENT® (alirocumab) Summary of Product Characteristics, Sanofi/Regeneron Pharmaceuticals, 2015, last revision date in UAE & Kuwait September 2016

For further medical information, please contact the following: For UAE: 890 Medical Toll Free Number. For all Gulf Countries: medical-information.gulf@sanofi.com
Full prescribing information is available upon request at Sanofi Regional Office, Jumeirah Lakes Towers, Dubai, UAE. To report adverse events, please call +971 50 747 7001 Email: Gulf.Pharma.sanofi.com www.sanofi.com
Sanofi and Regeneron are collaborating in a global development program and commercialisation for PRALUENT.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

Website: www.boehringer-ingelheim.com

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

Website: www.boehringer-ingelheim.com

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its manufacturing expertise to strive for solutions dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential

Website: www.amgen.com

Exhibitor

Bayer

Bayer is an innovation company with a more than 150-year history and core competencies in the fields of health care and agriculture. We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms. An analysis by well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion. Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing mankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.

Website: www.middleeast.bayer.com

Bayer

Bayer is an innovation company with a more than 150-year history and core competencies in the fields of health care and agriculture. We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms. An analysis by well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion. Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing mankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.

Website: www.middleeast.bayer.com

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its manufacturing expertise to strive for solutions dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential

Website: www.amgen.com
CME Information:
• This Conference is CME accredited with 13.25 CME Credit Hours by Ministry of Health And Prevention.
• Please scan your badge every time you enter to the conference Hall.
• CME Certificates can be obtained starting March 12th, 2019, through the Conference website: www.CVUAE.com
• Delegates should log in using the registration number on their badge.
• Fill the evaluation form and you will be able to download your certificate.
• Kindly use Laptop/Desktop computers to download the certificates.
• The deadline to download the Certificate is April 30th, 2019.

Food & Beverage:
• Coffee break will be open to registered delegates.
• Meal will be offered against the voucher provided with the delegate badges.
• There is an ATM machine conveniently located next to the elevators in the forum venue.
• The conference venue is a non-smoking venue. Participants are requested to visit designated smoking corners when smoking is desired.

Regulations:
• Mobile Phones: As courtesy to the other delegates, please ensure that your mobile phone is switched to silent while in the main room.

Parking:
• Paid parking is available at the venue.

Internet Access:
• Wi-fi Internet access is available in all public areas in the forum Venue.
Internet connection: DHCA-Guest
Username: dhcc
Password: DHCC@123

EVACUATION ASSEMBLY POINT: In case of an emergency evacuation procedure please proceed in an orderly fashion to the venue main entrance. Please follow the instructions of the venue Staff at all times.
The Organizing Committee would like to express its gratitude to the following companies for their unconditional support to this activity.

**ACKNOWLEDGMENT**

**MAIN SPONSOR**

**GOLD SPONSOR**

**PLATINUM SPONSORS**

**TITANIUM SPONSOR**

**SUPPORT SPONSORS**

**EXHIBITOR**

**MEDIA PARTNERS**

See you Next Year

February 28th & 29th, 2020